Pacific Edge Limited (PFGTF)

1.2000 0.0000 (0.00%) At close: 09:30AM EDT

Pacific Edge Limited

Centre for Innovation
87 St David Street PO Box 56
Dunedin 9016
New Zealand
64 3 479 5800
https://www.pacificedgedx.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Peter Meintjes	Chief Exec. Officer	N/A	N/A	N/A
Mr. Grant Gibson	Chief Financial Officer	N/A	N/A	N/A
Ms. Demi Stefanova	Chief Operating Officer	N/A	N/A	N/A
Mr. Justin Harvey	Chief Technology Officer	N/A	N/A	N/A
Dr. Parry Guilford Ph.D.	Chief Scientific Officer & Member of Scientific Advisory Board	83.69k	N/A	N/A
Mr. Jack Atchason	Sr. VP of Sales & Customer Service, Pacific Edge Diagnostics USA Limited	N/A	N/A	N/A
Mr. Andrew McIntosh	Chief of Information Systems & Decision Support	N/A	N/A	N/A
Ms. Jacqueline F. Walker	Chief Exec. Officer of Pacific Edge Diagnostics USA	N/A	N/A	N/A
Mr. Tony Lough	VP of Clinical Science & Product Performance, Pacific Edge Pty Limited	N/A	N/A	N/A
Mr. Brent Pownall	VP of Commercial & Franchise	N/A	N/A	N/A

Amounts are as of December 31, 2009 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, Singapore, and internationally. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product designed to identify high grade or late stage bladder cancer and provide increased clinical resolution; Cxbladder Triage, a product that analyses the gene expression of urine-based biomarkers alongside information on known bladder cancer risk factors like age, gender, and smoking history to rule out patients with a low risk of having the disease; Cxbladder Detect that can be used as an adjunct to cystoscopy or as a substitute for other urine-based tests or imaging procedures; and Cxbladder Monitor, which is a non-invasive and easy-to-use test to rule out the return of bladder cancer. In addition, the company is developing Cxcolorectal (prognosis Gen II), a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.

Corporate Governance

Pacific Edge Limited’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.